Your shopping cart


Total (VAT incl.)

VAT (21%)
You have not added any reports to the cart yet.
Request reports
If you prefer to place your order via e-mail
contact us at: digital@azierta.com

Events and news

Home > Blog > Toxicology

Key factors for the implementation of directive ICH and Q3D on elemental impurities

ICH Q3D Guideline is focused to limit the presence of potentially toxic elemental impurities in human medicines.

There are 4 issues to be taken into account before starting the risk analysis:

  • The strategies that we follow will largely depend on the suppliers’ baseline information.
  • The number of products requiring risk analysis, which will also influence the strategy to follow because of the impact on human and financial resources.
  • Usually, the pharmaceutical company does not have the analytical equipment for the determination of elemental impurities.
  • Neither the analytical plan nor the analytical cost can be considered without having analysed all the available baseline information.

On a practical level, the process for completing the risk analysis is as follows:

The implementation date of directive ICH Q3D on elemental impurities of December 2017 for marketed products will involve an important workload both in terms of human and economic resources.

At Azierta, we are experts in toxicology and EUROTOX corporate members. Our multidisciplinary team has AETOX, EUROTOX and ERT certified membersWe design and develop customized action plans for the implementation of ICH Q3D of elemental impurities, with a background of more than 600 reports completed or in progress, both on a national and international basis, which have already been assessed by health authorities.

Visit our website and fill out our form to gain access to practical advice on the implementation of ICH Q3D on elemental impurities.

If you would like to know more about us, please visit: Elemental impurities risk analysis


Related posts

What do you need for the cultivation of medicinal cannabis in...

What do you need for the cultivation of medicinal cannabis in Europe?

Read more

Azierta Webinar on the new requirements for Safety Data Sheets...

Azierta Webinar on the new requirements for Safety Data Sheets that will come into force on 1 January 2021

Read more

Leading innovation in pharma & health

100 professionals

Over 100 professionals

500 clients

Over 2,000 clients

9 year experience

10 years of experience


Leading innovation

Client oriented

100% client oriented


We help you in everything you need. Contact us by filling out the form or book an appointment for a video call with one of our experts.

We use "cookies" to improve your experience on our site. Cookies enable us to tailor messages and display ads to your interests. They also help us understand how our site is being used. By continuing to use our site you consent to use our cookies.

We are at your complete disposal for any inquiry

Thank you for getting in touch! We will contact you as soon as possible to help you out
There has been an error while submitting your form, please try again, or call us at 912 77 10 76